Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,407 across all filing types
Latest filing 2026-04-27 M&A Activity
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
General Updates
M&A Activity Classification · 100% confidence The document is a detailed announcement of a definitive agreement for Sun Pharmaceutical Industries Limited to acquire Organon. It includes transaction details, financial advisors, strategic rationale, and forward-looking statements. It references the upcoming filing of a proxy statement on Schedule 14A with the SEC related to the merger. The content is focused on merger and acquisition activity, including deal terms, approvals, and strategic impact. It is not a full annual report, earnings release, or regulatory certification. The presence of detailed merger terms and the announcement of the acquisition deal clearly classify this as a merger and acquisition announcement.
2026-04-27 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the incorporation of a new subsidiary company, Sun Pharma America, Inc. It provides details about the subsidiary, such as its name, nature of business, shareholding, and incorporation date. The document is a regulatory announcement about a corporate action (incorporation of a subsidiary) rather than a financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document length is 3782 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP), as it relates to corporate structuring and capital considerations for a new subsidiary.
2026-04-24 English
Updates
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification from Sun Pharmaceutical Industries Limited regarding the completion and results of a postal ballot held between 19 March 2026 and 17 April 2026. It announces the passing of shareholder resolutions including ratification of auditor remuneration, alteration of company objects, and re-appointment of an independent director. The document explicitly states it is informing about the voting results and references the Scrutinizer's Report being available on the company's website. The document length is short (1922 characters) and it serves as an official announcement of voting results rather than the detailed report itself. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-17 English
News Verification
Regulatory Filings Classification · 95% confidence The document is a letter from Sun Pharmaceutical Industries Limited addressed to stock exchanges (BSE and NSE) responding to a rumor verification request. It clarifies that the news about a potential deal is speculative and states there is no material event requiring disclosure under Regulation 30 of the Listing Regulations. The document is short (1731 characters) and serves as a regulatory communication to clarify market rumors rather than a financial report or announcement of a transaction. It does not contain financial data, management changes, voting results, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance communications that do not fit other specific categories.
2026-04-10 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the publication of newspaper advertisements related to Postal Ballot/E-Voting. It includes details about the advertisements published in newspapers and mentions that copies are attached as annexures and available on the company's website. There is no substantive financial data, financial statements, or detailed report content. The document is essentially an announcement of the publication of certain materials (newspaper advertisements) related to shareholder voting, not the voting results themselves or the full proxy materials. It is also not a full report like an Annual Report or Interim Report, nor a management discussion or earnings release. Given the nature of the document as a regulatory announcement about the publication of advertisements, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-08 English
Shareholders meeting
Board/Management Information Classification · 95% confidence The document is a detailed notice of a Postal Ballot/E-voting process for the appointment of an Independent Director at Sun Pharmaceutical Industries Limited. It includes the notice itself, explanatory statement, statutory notes, and procedural details. The content is focused on governance matters, specifically the appointment of a board member, and includes references to the Companies Act, SEBI Listing Regulations, and the nomination and remuneration committee's role. It is not a financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement but rather the notice and explanatory statement for a shareholder vote. This fits the category of Board/Management Information (MANG), as it announces a change in the company's board of directors.
2026-04-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.